Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
This is a multi-center, prospective, observational study designed to evaluate the impact
of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical
outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100
ev...
Age: 18 years - 66+
Gender: All
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy,
and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction
associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4
fibrosis...
Age: 18 - 75 years
Gender: All
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy,
and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction
associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4
fibrosis...
Age: 18 - 75 years
Gender: All
EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive
Prenatal Test. The development of this investigational single-gene noninvasive prenatal
testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy
(SMA), Sic...
Age: 18 years - 66+
Gender: All
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive
Prenatal Test. The development of this investigational single-gene noninvasive prenatal
testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy
(SMA), Sic...
Age: 18 years - 66+
Gender: All
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis
staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and
blood ...
Age: 18 - 89 years
Gender: All
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or
atezolizumab alone, as first-line treatment in participants with unresectable, locally
advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
Age: 18 years - 66+
Gender: All
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety and efficacy of atezolizumab and
bevacizumab, or atezolizumab alone, as first-line treatment in participants with
unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with
Child-Pugh B7 or B8 ci...
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Age: 21 years - 66+
Gender: All
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Age: 21 years - 66+
Gender: All
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic,
radiation). The safety and efficacy of oral ifetroban will be assessed in patients with
IPF.
Age: 40 years - 66+
Gender: All
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic,
radiation). The safety and efficacy of oral ifetroban will be assessed in patients with
IPF.
Age: 40 years - 66+
Gender: All
Renal Allograft Fibrosis Study
Despite the reduction in acute rejection episodes in renal transplant patients due to
modern immunosuppression, proportionate improvements in long-term allograft survival have
not been achieved. Virtually any disease or injury affecting renal allografts can
culminate...
Age: 18 years - 66+
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider
liver transplantation as an option, even if controversial. In sicker recipients, LT
results in immediate survival, but poor medium-term survival rates in some studies. The
scarcity...
Age: 18 - 80 years
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of...
Age: 18 - 80 years
Gender: All
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of
recombinant human pentraxin-2 (rhPTX-2; PRM-151) administered by intravenous (IV) infusion to
participants with idiopathic pulmonary fibrosis (IPF).
Age: Birth - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All